{"filings":[{"id":98647,"accession_number":"0001104659-26-051503","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BNB Plus stockholders approve reverse stock split authorization (1:5 to 1:30)","event_type":"other_material","confidence":"high","bullets":["Vote: 2,420,538 for, 317,840 against, 11,866 abstained on reverse split proposal.","Board granted 12-month discretion to set ratio between 1-for-5 and 1-for-30.","Number of authorized common shares to remain unchanged after split.","Adjournment proposal also approved (2,400,755 for, 314,899 against, 34,590 abstained)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114249,"accession_number":"0001104659-26-033842","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BNB Plus receives Nasdaq delisting notice for bid price non-compliance; ineligible for grace period","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BNB Plus on March 20, 2026 that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Mar 19.","Company is ineligible for a compliance cure period due to reverse stock splits in prior two years with cumulative ratio of 250:1 or more.","BNB Plus intends to timely request a hearing before Nasdaq Hearings Panel, which will automatically stay any suspension or delisting pending the process.","There is no assurance the Panel will grant continued listing or that the company can regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114248,"accession_number":"0001104659-26-010893","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BNB Plus appoints digital asset veteran James Haft as independent director","event_type":"leadership","confidence":"high","bullets":["James Haft appointed to board and Nominating Committee effective Feb 2, 2026.","Haft brings over 35 years experience in blockchain, digital assets, and traditional finance.","Compensation includes $40,000 cash fee and option grant of 93,000 shares at $1.31/share vesting over one year.","Appointment aims to support BNBX's treasury operations and DeFi yield generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114247,"accession_number":"0001104659-26-005784","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Elizabeth M. Schmalz Shaheen resigns from BNB Plus board effective Jan. 15, 2026","event_type":"leadership","confidence":"high","bullets":["Elizabeth M. Schmalz Shaheen resigned as director of BNB Plus on January 15, 2026.","Resignation was immediate; not due to any disagreement with the company.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130623,"accession_number":"0001104659-25-120899","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BNB Plus stockholders approve increase in authorized shares to 500M and amend equity plan","event_type":"other_material","confidence":"high","bullets":["Proposal to authorize exercisability of pre-funded warrants and issuance of underlying common stock passed with 1,642,390 votes for.","Amendment to Certificate of Incorporation increasing authorized common stock from 200M to 500M approved (1,971,926 for).","Amendment to 2020 Equity Incentive Plan to reserve an additional 5,000,000 shares approved (1,613,405 for).","All three proposals passed at special meeting on December 12, 2025; broker non-votes were present on two proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130622,"accession_number":"0001104659-25-113218","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Applied DNA rebrands to BNB Plus Corp., appoints Josh Kruger as Board Chairman","event_type":"other_material","confidence":"high","bullets":["Name changed to BNB Plus Corp. effective Nov 13, 2025; ticker remains BNBX on Nasdaq.","Josh Kruger appointed Chairman of the Board; Judy Murrah steps down as Chairperson but stays as director.","Rebrand aligns with a yield-optimized BNB-based digital asset treasury strategy using the Binance ecosystem.","Kruger is founder of OnChain Alpha and ex-Head of Trading at Coral Capital, acquired by DNA Fund in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130621,"accession_number":"0001104659-25-109267","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Applied DNA Sciences appoints Joshua Kruger as Chairman, replacing Judith Murrah","event_type":"leadership","confidence":"high","bullets":["Appointment effective November 6, 2025; Kruger also becomes director, filling vacancy from Sanford Simon's resignation.","Kruger holds ~33% economic interest in Cypress entities providing advisory and asset management services to the company.","Strategic Advisor Agreement includes $60,000 monthly fee and warrants to purchase 1,986,634 shares issued to Cypress Management LLC.","Kruger individually purchased 75,302 shares and warrants for $250,002.64 in October 2025 private placements.","Murrah resigned as Chair but remains on board; Kruger is not independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130620,"accession_number":"0001104659-25-105945","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Applied DNA Sciences enters $8.16M ATM offering and consulting deal with Patrick Horsman","event_type":"other_material","confidence":"medium","bullets":["ATM agreement with Lucid Capital Markets for up to $8,157,932 of common stock at market prices.","Agent commission 3.0% of gross sales price; estimated offering commencement expenses ~$175,000.","Consulting agreement with Patrick Horsman effective Oct 1, 2025, requires 75% work time commitment.","Consulting agreement includes 12-month severance if terminated without cause and IP assignment to company.","Consulting references BNB digital asset strategy; no compensation amount specified in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130619,"accession_number":"0001104659-25-101630","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Applied DNA closes $27M PIPE, buys 15,555 BNB tokens, launches digital asset treasury","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$27M from PIPE, with potential additional $31M from warrant exercises.","Received $15.3M in cash/stablecoins and OBNB trust units valued at $11.71M representing 10,647 BNB tokens.","Purchased an additional 4,908 BNB tokens valued at ~$5.3M on October 20, 2025.","Streamlined operations achieving approximately $2.9M in annualized cost savings.","Company shifts to yield-focused BNB digital asset treasury strategy led by new CIO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130618,"accession_number":"0001104659-25-097097","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Applied DNA cuts 60% of workforce ($1.4M charges), ticker changes to BNBX Oct 7","event_type":"other_material","confidence":"high","bullets":["Reduces workforce by 16 employees (~60%) with estimated pre-tax charges of ~$1.4M for severance and benefits.","Restructuring substantially complete by end of October 2025; annualized cost savings of ~$2.9M expected.","Ticker symbol changes from APDN to BNBX on Nasdaq effective October 7, 2025, reflecting BNB treasury strategy.","Company to focus on yield-generating BNB digital asset treasury and decentralized finance integration.","No stockholder action required; CUSIP and listing unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130617,"accession_number":"0001104659-25-095401","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"APDN raises $27M via PIPE for BNB treasury strategy; CEO replaced, ticker to change to BNBX","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$27M from private placement of shares & warrants; up to $58M if warrants exercised; proceeds to acquire BNB tokens.","CEO Judith Murrah resigned; Clay Shorrock (former Chief Legal Officer) appointed as President & CEO effective Sept 29, 2025.","New advisors: Anthony Scaramucci (SkyBridge), Patrick Horsman (CIO), Josh Kruger (Chairman nominee), JR Pasch.","Company to change ticker to BNBX; plans BNB treasury strategy with active DeFi yield generation via Cypress LLC.","Entered 5-year DAS with Cypress LLC (1.25% mgmt fee + 10% incentive) and advisor agreement with Cypress Management ($60k/month + 9.5% warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147166,"accession_number":"0001104659-25-094465","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","3.02","5.02","8.01"],"status":"ready","headline":"Applied DNA Sciences raises $26.8M, appoints new CEO, adopts BNB treasury strategy","event_type":"other_material","confidence":"high","bullets":["Raised approximately $26.8 million via private placement selling 4.73M shares and warrants at $3.82 per share.","CEO Judith Murrah stepped down on Sept 29, 2025; Clay Shorrock appointed as new CEO effective same day.","Entered strategic digital assets services agreement with Cypress LLC for discretionary management of BNB and other crypto.","Engaged Cypress Management LLC as strategic advisor with $60,000 monthly fee and warrants for 9.5% of outstanding shares.","Offered securities under Section 4(a)(2) and Rule 506(b) of Regulation D; securities are unregistered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147165,"accession_number":"0001104659-25-078611","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Applied DNA Q3 FY2025 revenue $304K, operating loss $3.7M; cash burn improves 19% sequentially","event_type":"earnings","confidence":"high","bullets":["Total revenues $304K (down 36% YoY from $473K); operating loss $3.7M vs $3.3M loss in prior year.","Adjusted EBITDA negative $3.9M; monthly net cash burn $934K, down 19% sequentially and 25% YoY.","Received follow-on LineaDNA order >$600K from IVD manufacturer; added new U.S. mRNA CDMO customer.","Cash and equivalents $4.7M at June 30, 2025, including $723K from warrant exercises.","Company closed MDx Testing Services (discontinued ops) and executed 1:15 reverse stock split in June."],"consensus_eps_estimate":null,"consensus_eps_actual":-256.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1937506.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147164,"accession_number":"0001104659-25-066078","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Applied DNA regains Nasdaq minimum bid price compliance; hearing cancelled","event_type":"other_material","confidence":"high","bullets":["On July 2, 2025, Nasdaq notified Applied DNA it regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).","The July 15, 2025 hearing before the Nasdaq Hearings Panel has been cancelled.","Applied DNA's common stock will continue to be listed and traded on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165753,"accession_number":"0001104659-25-064106","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.","One-time charges of ~$300k; majority of costs expected by Sept 30, 2025.","CEO Judy Murrah takes 15% salary reduction to $340k/year.","Company ends May 2025 with ~$4.8M cash; cumulative headcount reduction of 39% since Dec 2024.","Restructuring positions LineaRx synthetic DNA manufacturing as sole focus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165752,"accession_number":"0001104659-25-060258","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Applied DNA CEO James Hayward retires; President Judy Murrah named CEO and Chair","event_type":"leadership","confidence":"high","bullets":["CEO and Chairman James Hayward retires effective June 18, 2025, after 20-year tenure.","Hayward receives $450,000 separation paid over 8 months; first installment by July 15, 2025.","President Judy Murrah appointed CEO, Chairperson, and Board director effective June 18, 2025.","Murrah retains $400,000 annual base salary; no additional board compensation.","Murrah previously President and COO; background includes leadership at Symbol Technologies and Motorola."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165751,"accession_number":"0001104659-25-057222","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Applied DNA Sciences receives Nasdaq delisting notice for bid price deficiency; requests hearing","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified APDN on May 30, 2025 that bid price closed below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).","APDN executed a 1-for-15 reverse stock split on June 2, 2025 to address deficiency, but is ineligible for a compliance period due to prior reverse splits.","Company timely requested a hearing before Nasdaq Hearings Panel on June 6, 2025, which stays any suspension or delisting pending outcome.","No assurance that the Panel will grant continued listing; shares remain at risk of delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165750,"accession_number":"0001104659-25-053914","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Applied DNA announces 1-for-15 reverse stock split effective June 2, 2025","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-15; effective 12:01 a.m. ET on June 2, 2025.","Outstanding shares reduce from ~7.8M to ~519K; fractional shares rounded up to nearest whole.","Stock continues trading on Nasdaq under ticker APDN with new CUSIP 03815U607.","Split intended to bring company into compliance with Nasdaq $1.00 minimum bid price requirement.","Board approved ratio on May 27, 2025; stockholder authorization obtained at May 22 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165749,"accession_number":"0001104659-25-051992","cik":744452,"company_name":"BNB PLUS CORP.","ticker":"BNBX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Applied DNA shareholders approve reverse split, warrant exercise, share increase at annual meeting","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected (Hayward, Catell, Ceccoli, Shamash, Simon, Shaheen) with average ~572K for vs ~117K withheld.","Ratification of CBIZ CPAs P.C. as auditor approved (2.24M for, 108K against, 14.5K abstain).","Reverse stock split authorization approved (1.71M for, 654K against) with ratio range from 1:5 to 1:50 determined by board.","Exercisability of warrants from Oct 2024 offering approved (553K for, 131K against, 1.67M broker non-votes).","Equity plan share increase by 3M shares approved (478.5K for, 208.5K against, 1.67M broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}